XML 20 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
Notes Payable and Convertible Notes Payable (Details Narrative) (USD $)
3 Months Ended
Mar. 31, 2015
Sep. 30, 2014
Debt Disclosure [Abstract]    
Convertible notes, annual interest rate 12.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage  
Convertible notes, conversion price $ 0.15us-gaap_DebtInstrumentConvertibleConversionPrice1  
Unamortized discount on convertible notes outstanding $ 295,968us-gaap_DebtInstrumentUnamortizedDiscount $ 0us-gaap_DebtInstrumentUnamortizedDiscount
Face value of convertible notes issued by Regen Biopharma 882,686us-gaap_NotesIssued1  
Cash consideration for issued notes by Regen Biopharma 775,000us-gaap_ProceedsFromConvertibleDebt  
Satisfaction of existing indebtedness 107,686us-gaap_ExtinguishmentOfDebtAmount  
Common shares issued upon conversion of notes payable 31,539,262us-gaap_DebtConversionConvertedInstrumentSharesIssued1  
Series A preferred shares issued upon conversion of notes payable 31,538,862BMSN_DebtConversionConvertedInstrumentPreferredSharesIssued1  
Derivative liability $ 2,368,685us-gaap_IncreaseDecreaseInDerivativeLiabilities